182 related articles for article (PubMed ID: 15953490)
1. Are there differences in the symptoms that respond to a selective serotonin or norepinephrine reuptake inhibitor?
Nelson JC; Portera L; Leon AC
Biol Psychiatry; 2005 Jun; 57(12):1535-42. PubMed ID: 15953490
[TBL] [Abstract][Full Text] [Related]
2. Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine.
Nelson JC; Portera L; Leon AC
J Clin Psychiatry; 2005 Nov; 66(11):1409-14. PubMed ID: 16420078
[TBL] [Abstract][Full Text] [Related]
3. Noradrenaline-selective versus serotonin-selective antidepressant therapy: differential effects on social functioning.
Dubini A; Bosc M; Polin V
J Psychopharmacol; 1997; 11(4 Suppl):S17-23. PubMed ID: 9438229
[TBL] [Abstract][Full Text] [Related]
4. Reboxetine versus fluoxetine: an overview of efficacy and tolerability.
Massana J
J Clin Psychiatry; 1998; 59 Suppl 14():8-10. PubMed ID: 9818624
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: a single-blind, randomized clinical trial.
Taner E; Demir EY; Cosar B
Adv Ther; 2006; 23(6):974-87. PubMed ID: 17276965
[TBL] [Abstract][Full Text] [Related]
6. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression.
Andreoli V; Caillard V; Deo RS; Rybakowski JK; Versiani M
J Clin Psychopharmacol; 2002 Aug; 22(4):393-9. PubMed ID: 12172339
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of reboxetine in major depression.
Schatzberg AF
J Clin Psychiatry; 2000; 61 Suppl 10():31-8. PubMed ID: 10910015
[TBL] [Abstract][Full Text] [Related]
8. Do noradrenaline and serotonin differentially affect social motivation and behaviour?
Dubini A; Bosc M; Polin V
Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S49-55; discussion S71-3. PubMed ID: 9169310
[TBL] [Abstract][Full Text] [Related]
9. The impact of antidepressant use on social functioning: reboxetine versus fluoxetine.
Venditti LN; Arcelus A; Birnbaum H; Greenberg P; Barr CE; Rowland C; Williamson T
Int Clin Psychopharmacol; 2000 Sep; 15(5):279-89. PubMed ID: 10993130
[TBL] [Abstract][Full Text] [Related]
10. Reboxetine: its effects as measured by the Social Adaptation Self-evaluation Scale.
Healy D
Acta Psychiatr Scand Suppl; 2000; 402():45-51. PubMed ID: 10901159
[TBL] [Abstract][Full Text] [Related]
11. Prediction of the response to citalopram and reboxetine in post-stroke depressed patients.
Rampello L; Chiechio S; Nicoletti G; Alvano A; Vecchio I; Raffaele R; Malaguarnera M
Psychopharmacology (Berl); 2004 Apr; 173(1-2):73-8. PubMed ID: 14685645
[TBL] [Abstract][Full Text] [Related]
12. Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder.
Versiani M; Cassano G; Perugi G; Benedetti A; Mastalli L; Nardi A; Savino M
J Clin Psychiatry; 2002 Jan; 63(1):31-7. PubMed ID: 11838623
[TBL] [Abstract][Full Text] [Related]
13. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder.
Versiani M; Mehilane L; Gaszner P; Arnaud-Castiglioni R
J Clin Psychiatry; 1999 Jun; 60(6):400-6. PubMed ID: 10401920
[TBL] [Abstract][Full Text] [Related]
14. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study.
Nelson JC; Mazure CM; Jatlow PI; Bowers MB; Price LH
Biol Psychiatry; 2004 Feb; 55(3):296-300. PubMed ID: 14744472
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of a social functioning scale, the Social Adaptation Self-evaluation Scale.
Bosc M; Dubini A; Polin V
Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S57-70; discussion S71-3. PubMed ID: 9169311
[TBL] [Abstract][Full Text] [Related]
16. Assessment of social functioning in depression.
Bosc M
Compr Psychiatry; 2000; 41(1):63-9. PubMed ID: 10646621
[TBL] [Abstract][Full Text] [Related]
17. No effects of antidepressants on negative symptoms in schizophrenia.
Hinkelmann K; Yassouridis A; Kellner M; Jahn H; Wiedemann K; Raedler TJ
J Clin Psychopharmacol; 2013 Oct; 33(5):686-90. PubMed ID: 23857309
[TBL] [Abstract][Full Text] [Related]
18. Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study.
Seedat S; van Rheede van Oudtshoorn E; Muller JE; Mohr N; Stein DJ
Int Clin Psychopharmacol; 2003 Sep; 18(5):279-84. PubMed ID: 12920388
[TBL] [Abstract][Full Text] [Related]
19. Reboxetine induces similar sleep-EEG changes like SSRI's in patients with depression.
Kuenzel HE; Murck H; Held K; Ziegenbein M; Steiger A
Pharmacopsychiatry; 2004 Sep; 37(5):193-5. PubMed ID: 15359374
[TBL] [Abstract][Full Text] [Related]
20. Differential prediction of first clinical response to serotonergic and noradrenergic antidepressants using the loudness dependence of auditory evoked potentials in patients with major depressive disorder.
Juckel G; Pogarell O; Augustin H; Mulert C; Müller-Siecheneder F; Frodl T; Mavrogiorgou P; Hegerl U
J Clin Psychiatry; 2007 Aug; 68(8):1206-12. PubMed ID: 17854244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
